Список литературы

Поставить закладку

Менделеева Л.П., Вотякова О.М., Рехтина И.Г. Множественная миелома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. / ed. Поддубной И.В., Савченко В.Г. Москва, 2018. 213–241 p.
Furukawa Y., Kikuchi J. Molecular pathogenesis of multiple myeloma. // Int. J. Clin. Oncol. 2015. Vol. 20, № 3. P. 413–422.
Lewis E.B. Leukemia, Multiple Myeloma, and Aplastic Anemia in American Radiologists // Science (80-. ). 1963. Vol. 142, № 3598. P. 1492–1494.
Linet M.S., Harlow S.D., McLaughlin J.K. A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use. // Cancer Res. 1987. Vol. 47, № 11. P. 2978–2981.
Hallek M., Bergsagel P.L., Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process. // Blood. 1998. Vol. 91, № 1. P. 3–21.
Kuehl W.M., Bergsagel P.L. Molecular pathogenesis of multiple myeloma and its premalignant precursor. // J. Clin. Invest. 2012. Vol. 122, № 10. P. 3456–3463.
Morgan G.J., Walker B.A., Davies F.E. The genetic architecture of multiple myeloma. // Nat. Rev. Cancer. 2012. Vol. 12, № 5. P. 335–348.
Fonseca R. et al. International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review // Leukemia. Nature Publishing Group, 2009. Vol. 23, № 12. P. 2210–2221.
Бессмельцев С.С. Множественная миелома // Вестник гематологии. 2014. Vol. 10, № 3. P. 6–39.
Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival // Cancer. 1975. Vol. 36, № 3. P. 842–854.
Greipp P.R. et al. International staging system for multiple myeloma // J. Clin. Oncol. 2005. Vol. 23, № 15. P. 3412–3420.
Palumbo A. et al. Revised international staging system for multiple myeloma: A report from international myeloma working group // J. Clin. Oncol. 2015.
D’agostino M. et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project // J. Clin. Oncol. Lippincott Williams and Wilkins, 2022. Vol. 364.
Rajkumar S.V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma // Lancet Oncol. Elsevier Ltd, 2014. Vol. 15, № 12. P. e538–e548.
Kyle R.A., Rajkumar S. V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. // Leukemia. 2009. Vol. 23, № 1. P. 3–9.
Moreau P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2017. Vol. 28, № suppl_4. P. iv52–iv61.
Coppola A. et al. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. // Semin. Thromb. Hemost. 2011. Vol. 37, № 8. P. 929–945.
Tripathy S. The role of serum protein electrophoresis in the detection of multiple myeloma: An experience of a corporate hospital // J. Clin. Diagnostic Res. 2012. Vol. 6, № 9. P. 1458–1461.
Misra A. et al. Old but Still Relevant: High Resolution Electrophoresis and Immunofixation in Multiple Myeloma // Indian Journal of Hematology and Blood Transfusion. Springer India, 2016. Vol. 32, № 1. P. 10–17.
Любимова Н.В. et al. Свободные легкие цепи иммуноглобулинов в диагностике и прогнозе множественной миеломы. // Альманах клинической медицины. 2017. Vol. 45, № 2. P. 102–108.
Julie D. et al. Comparison of Bone marrow Aspirate and Bone marrow Biopsy in the workup of Patients with Multiple Myeloma // Clin. Lymphoma Myeloma Leuk. Elsevier BV, 2015. Vol. 15. P. e117.
Pianko M.J. et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease // Clinical Cancer Research. American Association for Cancer Research Inc., 2014. Vol. 20, № 23. P. 5888–5897.
Cavo M. et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. // Lancet. Oncol. 2017. Vol. 18, № 4. P. e206–e217.
Mateos M.-V., San Miguel J. V. Smoldering multiple myeloma // Hematol. Oncol. 2015. Vol. 33. P. 33–37.
Zou Y. et al. Bortezomib and lenalidomide as front-line therapy for multiple myeloma. // Leuk. Lymphoma. 2014. Vol. 55, № 9. P. 2024–2031.
Mateos M.V. et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial // J. Clin. Oncol. 2010. Vol. 28, № 13. P. 2259–2266.
Bringhen S. et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. // Blood. 2010. Vol. 116, № 23. P. 4745–4753.
Takezako N. et al. The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients // Blood. 2016. Vol. 128, № 22.
Jagannath S. et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. // Br. J. Haematol. 2009. Vol. 146, № 6. P. 619–626.
Rampotas A. et al. Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients // Eur. J. Haematol. Eur J Haematol, 2021. Vol. 106, № 4. P. 563–573.
Saeed N. et al. Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment // Cureus. Cureus, 2024. Vol. 16, № 4.
Dimopoulos M.A. et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† // Ann. Oncol. Elsevier, 2021. Vol. 32, № 3. P. 309–322.
Weisel K. et al. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. // Leuk. Lymphoma. 2017. Vol. 58, № 1. P. 153–161.
Benboubker L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma // N. Engl. J. Med. Massachussetts Medical Society, 2014. Vol. 371, № 10. P. 906–917.
Facon T. et al. Updated Overall Survival (OS) Analysis of the FIRST Study: Lenalidomide Plus Low-Dose Dexamethasone (Rd) Continuous vs Melphalan, Prednisone, and Thalidomide (MPT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) // Clin. Lymphoma Myeloma Leuk. Elsevier BV, 2015. Vol. 15. P. e134.
Palumbo A. et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. // N. Engl. J. Med. 2012. Vol. 366, № 19. P. 1759–1769.
Facon T. et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma // N. Engl. J. Med. Massachusetts Medical Society, 2019. Vol. 380, № 22. P. 2104–2115.
Mateos M. V. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma // N. Engl. J. Med. Massachussetts Medical Society, 2018. Vol. 378, № 6. P. 518–528.
Mateos M.V. et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial // Lancet Haematol. Elsevier, 2020. Vol. 7, № 5. P. e370–e380.
Usmani S.Z. et al. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma // Haematologica. Ferrata Storti Foundation, 2022. Vol. 107, № 10. P. 2408–2417.
Durie B.G.M. et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) // Blood Cancer J. Springer Nature, 2020. Vol. 10, № 5.
Durie B.G.M. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial // Lancet. Lancet Publishing Group, 2017. Vol. 389, № 10068. P. 519–527.
Larocca A. et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) // Leukemia. 2018. Vol. 32. P. 1697–1712.
Kapoor P. et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis // Leuk. 2011 254. Nature Publishing Group, 2011. Vol. 25, № 4. P. 689–696.
Gregory W.M., Richards M.A., Malpas J.S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. // https://doi.org/10.1200/JCO.1992.10.2.334. Lippincott Williams and Wilkins, 2016. Vol. 10, № 2. P. 334–342.
Su B. et al. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents // Leuk. Lymphoma. Taylor and Francis Ltd, 2018.
Dhakal B. et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction a systematic review and meta-analysis // JAMA Oncol. American Medical Association, 2018. Vol. 4, № 3. P. 343–350.
Nooka A.K. et al. Bortezomib-containing induction regimens in transplant-eligible myeloma patients // Cancer. 2013. Vol. 119, № 23. P. 4119–4128.
Leiba M. et al. Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: A meta-analysis // Br. J. Haematol. Blackwell Publishing Ltd, 2014. Vol. 166, № 5. P. 702–710.
Attal M. et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2017. Vol. 376, № 14. P. 1311–1320.
Rosiñol L. et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma // Blood. American Society of Hematology, 2019. Vol. 134, № 16. P. 1337–1345.
Tuchman S.A., Chao N.J., Gasparetto C.G. Lenalidomide before and after autologous hematopoietic stem cell transplantation in multiple myeloma // Advances in Hematology. 2012. Vol. 2012.
Knop S. et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom) // Blood. 2009. Vol. 113, № 18. P. 4137–4143.
Reece D.E. et al. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma // Br. J. Haematol. Blackwell Publishing Ltd, 2015. Vol. 168, № 1. P. 46–54.
Fung H.C., Nathan S., Maciejewski J.J. Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma - does it matter? // Clin. Pharmacol. 2010. Vol. 2. P. 71–75.
Tuchman S.A. et al. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma // J. Clin. Apher. Wiley-Liss Inc., 2015. Vol. 30, № 3. P. 176–182.
Hosing C. Hematopoietic stem cell mobilization with G-CSF // Methods Mol. Biol. Humana Press Inc., 2012. Vol. 904. P. 37–47.
Sivaraj D. et al. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma // Bone Marrow Transplant. Nature Publishing Group, 2018. Vol. 53, № 1. P. 34–38.
Oliva S. et al. Minimal residual disease after transplantation or lenalidomidebased consolidation in myeloma patients: A prospective analysis // Oncotarget. Impact Journals LLC, 2017. Vol. 8, № 4. P. 5924–5935.
Sonneveld P. et al. Consolidation followed by maintenance vs. maintenance alone in newly diagnosed, transplant eligible multiple myeloma: a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM TRIAL) // EHA 23 Proceedings. 2018. P. Abstract S108.
Roussel M. et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo // J. Clin. Oncol. American Society of Clinical Oncology, 2014. Vol. 32, № 25. P. 2712–2717.
Naumann-Winter F. et al. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. // Cochrane database Syst. Rev. 2012. Vol. 10. P. CD004626.
Nathwani N., Larsen J.T., Kapoor P. Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents // Current Hematologic Malignancy Reports. 2016.
Sonneveld P. et al. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial // J. Clin. Oncol. 2012. Vol. 30, № 24. P. 2946–2955.
McCarthy P.L. et al. Lenalidomide after stem-cell transplantation for multiple myeloma. // N. Engl. J. Med. 2012. Vol. 366, № 19. P. 1770–1781.
Attal M. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. // N. Engl. J. Med. 2012. Vol. 366, № 19. P. 1782–1791.
Palumbo A. et al. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma // N. Engl. J. Med. 2014. Vol. 371, № 10. P. 895–905.
Beurden-Tan C.H.Y.V. et al. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma // Journal of Clinical Oncology. American Society of Clinical Oncology, 2017. Vol. 35, № 12. P. 1312–1319.
Knopf K.B. et al. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. // Clin. Lymphoma. Myeloma Leuk. 2014. Vol. 14, № 5. P. 380–388.
Scott K. et al. Bortezomib for the treatment of multiple myeloma. // Cochrane database Syst. Rev. 2016. Vol. 4. P. CD010816.
Dimopoulos M.A. et al. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis // Clin. Lymphoma, Myeloma Leuk. Elsevier Inc., 2018. Vol. 18, № 3. P. 163-173.e6.
Anderson K.C. et al. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study // J. Clin. Oncol. 2009. Vol. 27, № 15 (Suppl.). P. Abstract 8536.
Dimopoulos M. et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study // Lancet. Elsevier, 2020. Vol. 396, № 10245. P. 186–197.
Moreau P. et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial // Lancet. Elsevier, 2021. Vol. 397, № 10292. P. 2361–2371.
Shah C. et al. Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: Systematic review and meta-analysis of 14 trials // Oncotarget. Impact Journals LLC, 2018. Vol. 9, № 34. P. 23704–23717.
Dimopoulos M.A. et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial // Lancet Oncol. Lancet Publishing Group, 2017. Vol. 18, № 10. P. 1327–1337.
Moreau P. et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma // N. Engl. J. Med. 2016. Vol. 374, № 17. P. 1621–1634.
Bahlis N.J. et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study // Leukemia. Nature Publishing Group, 2020. Vol. 34, № 7. P. 1875.
Mateos M.V. et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR // Clin. Lymphoma Myeloma Leuk. Elsevier, 2020. Vol. 20, № 8. P. 509–518.
Dimopoulos M.A. et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial // Cancer. John Wiley and Sons Inc., 2018. Vol. 124, № 20. P. 4032–4043.
Miguel J.S. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial // Lancet Oncol. 2013. Vol. 14, № 11. P. 1055–1066.
Lokhorst H.M. et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. // N. Engl. J. Med. 2015. Vol. 373, № 13. P. 1207–1219.
Lonial S. et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial // Lancet. Lancet Publishing Group, 2016. Vol. 387, № 10027. P. 1551–1560.
Dimopoulos M.A. et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2018. Vol. 379, № 19. P. 1811–1822.
Attal M. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study // Lancet. Lancet Publishing Group, 2019. Vol. 394, № 10214. P. 2096–2107.
Dimopoulos M.A. et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial // Lancet Oncol. Elsevier, 2021. Vol. 22, № 6. P. 801–812.
Tsang R.W. et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. // Int. J. Radiat. Oncol. Biol. Phys. 2018. Vol. 101, № 4. P. 794–808.
Mark D. et al. Local Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine. // Front. Oncol. 2019. Vol. 9. P. 601.
Sonneveld P., Broijl A. Treatment of relapsed and refractory multiple myeloma // Haematologica. Ferrata Storti Foundation, 2016. Vol. 101, № 4. P. 396–406.
Punke A.P., Waddell J.A., Solimando D.A. Lenalidomide, bortezomib, and dexamethasone (RVD) regimen for multiple myeloma // Hosp. Pharm. SAGE Publications Ltd, 2017. Vol. 52, № 1. P. 27–32.
Dimopoulos M.A. et al. Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group // Journal of Clinical Oncology. American Society of Clinical Oncology , 2010. Vol. 28, № 33. P. 4976–4984.
Соловьев М.В., Соловьева М.В., Менделеева Л.П. Сопроводительная терапия при множественной миеломе: практические рекомендации // Клиническая онкогематология. 2023. Vol. 16, № 4. P. 426–448.
Compagno N. et al. Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia // Front. Immunol. Frontiers Media SA, 2014. Vol. 5, № DEC.
Roy V. et al. Hematopoietic Growth Factors. NCCN Guidelines. Ver 1.2022. 2022.
Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России., 2016. 94 p.
Durie B.G.M. et al. International uniform response criteria for multiple myeloma // Leukemia. Nature Publishing Group, 2006. Vol. 20, № 9. P. 1467–1473.
Rajkumar S.V. et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1 // Blood. 2011. Vol. 117, № 18. P. 4691–4695.
Kumar S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma // Lancet Oncol. Elsevier, 2016. Vol. 17, № 8. P. e328–e346.
Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am. J. Phys. Med. Rehabil. 2011. Vol. 90, № 5 Suppl 1. P. S88-94.
Jones J.R. et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial // Blood Cancer J. 2016. Vol. 6, № 12. P. e506.
Rajkumar S.V. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial // Lancet Oncol. Lancet Publishing Group, 2010. Vol. 11, № 1. P. 29–37.
Weisel K. et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 MAIA study // HemaSphere. Wolters Kluwer Health, 2023. Vol. 7, № Suppl.
Popat R. et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up // Br. J. Haematol. John Wiley & Sons, Ltd, 2008. Vol. 141, № 4. P. 512–516.
Dadacaridou M. et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. // J. BUON. Vol. 12, № 1. P. 41–44.
Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group // Am. J. Clin. Oncol. 1982. Vol. 5, № 6. P. 649–655.